CAS RN: 2095128-17-7
MA-0204
Product Availability
Choose a grade to view its available package options.
6 package records4 with current stock1 grade group
| Batch No. | Package | Availability | Warehouse | Lead Time | Inquiry |
| Batchno.20250203 |
100mg |
Out of stock |
| | Inquiry |
| Batchno.20250729 |
10mg |
In stock |
Shanghai | | Inquiry |
| Batchno.20260124 |
25mg |
In stock |
Shanghai | | Inquiry |
| Batchno.20251018 |
50mg |
In stock |
Shanghai | | Inquiry |
| Batchno.20251011 |
5mg |
In stock |
Shanghai | | Inquiry |
| Batchno.20250420 |
5mg / 10mg |
Out of stock |
| 5-7 business days | Inquiry |
-
Product code:
starshine_CAS2095128-17-7
-
Purity/Analytical Methods:
>99.0%
GET A QUOTE
2095128-17-7 / (3R)-3-methyl-6-[2-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]imidazol-1-yl]methyl]phenoxy]hexanoic acid
Standard CAS: 2095128-17-7
Multi CAS: No
Basic Information
CAS
2095128-17-7
Multi CAS
No
Molecular Formula
C25H27F3N2O4
Molecular Weight
476.500000
Exact Mass
476.192292
SMILES
CC1=CN=C(N1CC2=CC=CC=C2OCCC[C@@H](C)CC(=O)O)C3=CC=C(C=C3)OC(F)(F)F
InChI
InChI=1S/C25H27F3N2O4/c1-17(14-23(31)32)6-5-13-33-22-8-4-3-7-20(22)16-30-18(2)15-29-24(30)19-9-11-21(12-10-19)34-25(26,27)28/h3-4,7-12,15,17H,5-6,13-14,16H2,1-2H3,(H,31,32)/t17-/m1/s1
InChIKey
GYNMVDMBFKGCCR-QGZVFWFLSA-N
Computed Properties
Structural Parameters
Heavy atom count
34
Aromatic heavy atom count
17
Fraction Csp3
0.36
Rotatable bonds
11
H-bond acceptors
5
H-bond donors
1
Molar refractivity
120.77
TPSA
73.58
LogP / Solubility
WLOGP
6.08
MLOGP
5.38
XLogP3
5.8
Consensus LogP
5.75
Log S (ESOL)
-6.27
Class (ESOL)
Insoluble
Log S (Ali)
-7.85
Class (Ali)
Insoluble
Log S (SILICOS-IT)
-9.12
Class (SILICOS-IT)
Insoluble
ADME
GI absorption
Low
BBB permeant
No
P-gp substrate
No
CYP1A2 inhibitor
Yes
CYP2C19 inhibitor
Yes
CYP2C9 inhibitor
Yes
CYP2D6 inhibitor
No
CYP3A4 inhibitor
Yes
Log Kp (skin permeation)
-1.31
Drug-likeness / Medicinal Chemistry
Lipinski
Yes
Ghose
No
Veber
No
Egan
No
Muegge
No
Bioavailability score
0.55
Brenk alerts
1
Leadlikeness
No
Synthetic Accessibility
3